Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $10.59, for a total value of $17,314.65. Following the transaction, the insider directly owned 3,594 shares of the company’s stock, valued at $38,060.46. The trade was a 31.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Trading Up 7.0%

NASDAQ:FDMT traded up $0.71 during mid-day trading on Wednesday, hitting $10.80. The stock had a trading volume of 904,864 shares, compared to its average volume of 1,057,282. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $12.34. The stock has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $6.43. The company has a market capitalization of $617.00 million, a PE ratio of -2.88 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on FDMT shares. Barclays dropped their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Royal Bank Of Canada boosted their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.70.

Institutional Trading of 4D Molecular Therapeutics

A number of large investors have recently made changes to their positions in FDMT. Armistice Capital LLC grew its stake in 4D Molecular Therapeutics by 265.3% during the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock worth $9,524,000 after buying an additional 796,000 shares during the last quarter. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $41,000. Prelude Capital Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after acquiring an additional 2,300 shares during the period. Parkman Healthcare Partners LLC purchased a new position in shares of 4D Molecular Therapeutics during the third quarter worth approximately $1,738,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $143,000. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.